FL-SUN-NUCLEAR
Sun Nuclear, a Mirion Medical company, today announced the upcoming version 5.0 release of its SunCHECK® software for comprehensive Quality Management in radiation therapy. The SunCHECK software is used globally by radiation therapy departments to manage delivery system oversight and patient-specific treatment quality --- all in one platform. SunCHECK Version 5.0 introduces a broad range of features and user-driven enhancements that optimize workflows and prioritize patient safety.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240429991805/en/
Sun Nuclear, a Mirion Medical company, announced the upcoming version 5.0 release of its SunCHECK® software for comprehensive Quality Management in radiation therapy. SunCHECK v5.0 addresses clinical workflow challenges with new treatment plan assessment capabilities, enhanced TPS/OIS integration, expanded QA device control, and worklist-based UI. (Graphic: Business Wire)
The Connected Workspace for Higher Quality
Toward a vision of a truly connected ecosystem for quality assurance in radiation therapy, key enhancements in SunCHECK v5.0 include:
- Better, earlier understanding of treatment plan quality and departmental standards from new plan feasibility evaluation and plan complexity metric features
- Stronger continuity of clinical goals and data management when moving from linac treatment planning system (TPS)/oncology information system (OIS) into the SunCHECK software
- Automation of time-intensive machine quality measurements with expanded device integration with the PC Electrometer™ device and 1D SCANNER™ water tank
- At-a-glance worklists and intuitive patient and machine workflows reflected in the refreshed user interface
“In each new release of SunCHECK, we are connecting and accelerating clinical workflows, while expanding compatibility so clinicians can work effectively — regardless of their department structure or equipment. By delivering efficiency gains and easing access to critical insights on treatment quality, we can help clinicians better focus on advancing care,” said Luis Rivera, Sun Nuclear Radiation Therapy President.
Demonstrations of the latest software will be available in the Sun Nuclear booth (#930) at the ESTRO Annual Meeting, May 3-7, in Glasgow, Scotland. Sun Nuclear will host a lunch symposium, with a welcome from Tom Logan, Mirion CEO, on Sunday, May 5.
"I’m pleased to join my Sun Nuclear colleagues at ESTRO as we debut this landmark evolution of the SunCHECK software. This upcoming release is a significant leap forward, offering high impact functionality to support healthcare providers in delivering optimal care to patients,” said Tom Logan, CEO of Mirion.
Learn more about the SunCHECK platform here.
About Sun Nuclear
Sun Nuclear is part of Mirion Medical, a group of healthcare-focused brands within Mirion. We provide innovative solutions for Radiation Therapy and Diagnostic Imaging centers. More than 5,000 cancer centers worldwide rely on us for independent, integrated Quality Management. With a focus on ongoing support, Sun Nuclear aims to ease technology adoption, enhance workflows and improve outcomes – so that healthcare providers can achieve real results for Patient Safety. Visit us: sunnuclear.com. Follow us: @sunnuclear.
Sun Nuclear, SunCHECK, 1D SCANNER, and PC Electrometer are trademarks or registered trademarks of Mirion Technologies, Inc. and/or its affiliates in the United States and/or other countries.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240429991805/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Vodafone Spain and Twilio Partner to Offer Secure and Interactive RCS Messaging to Businesses in Spain23.10.2025 10:00:00 CEST | Press release
81% of consumers prefer RCS over SMS, and 71% of businesses plan to adopt it in the next year. Twilio, the customer engagement platform that powers personalised, real-time experiences for today's leading brands, has announced an extended partnership with Vodafone Spain, one of the country's leading telecommunications operators. This will enable Spanish businesses to access Rich Communication Services (RCS) messaging, revolutionising the way they interact with their customers through rich, interactive and secure communications. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251023623745/en/ Vodafone Spain has relied on Twilio's global expertise to accelerate the adoption of this next-generation messaging solution, positioning it as the new standard for business communication in the Spanish market. A much needed evolution for mobile communication In a world where personalisation and trust are essential for brand to consumer re
AGC Biologics Partners with Rarity PBC to Advance Life-Saving Gene Therapy for "Bubble Baby Disease"23.10.2025 09:00:00 CEST | Press release
Collaboration will leverage AGC Biologics’ commercial manufacturing experience and proven platforms to seek regulatory approval for a therapy treating the rare immunodeficiency disorder, ADA-SCID. AGC Biologics, your friendly CDMO expert, today announced an agreement with Rarity PBC to provide comprehensive development and Good Manufacturing Practice (GMP) manufacturing for Rarity's gene therapy, RDP-101, for Adenosine Deaminase Severe Combined Immunodeficiency Disorder. If approved by the U.S. Food and Drug Administration, RDP-101 would be the first gene therapy available for commercial use to reverse ADA-SCID in patients within the United States. ADA-SCID is a rare, life-threatening inherited condition that severely compromises the immune system, leaving infants vulnerable to frequent and severe infections. For every million babies born worldwide, it is estimated that between one and five will have this condition. The ADA-SCID disorder caused by an Adenosine Deaminase deficiency is f
KILL TOURISE and Globant Unveil Game-Changing Report on Agentic Tourism that Sets New Standards for AI-Driven Destination Innovation23.10.2025 08:01:00 CEST | Press release
TOURISE requests that their press release NewsItemID: 20251022347041 “TOURISE and Globant Unveil Game-Changing Report on Agentic Tourism that Sets New Standards for AI-Driven Destination Innovation” be killed. The release was issued in error by TOURISE. A replacement release will be issued on October 23.
TOURISE and Globant Unveil Game-Changing Report on Agentic Tourism that Sets New Standards for AI-Driven Destination Innovation23.10.2025 08:01:00 CEST | Press release
Imagine a traveler’s perfect day planning itself, rerouting around a rainstorm, prompting a café to add staff before the lunch rush, suggesting a quiet gallery when crowds swell. This is the promise of Agentic Tourism, an AI-powered operating model introduced in a new white paper by TOURISE and Globant, a digitally native company that helps organizations thrive in a digital and AI-powered future, with strategic contribution from Kearney. The report, titled Tourism’s AI Takeover: Reinventing Travel through Agentic Tourism, presents a practical framework for transforming the tourism experience making it more seamless, intelligent, and emotionally resonant. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251022347041/en/ TOURISE and Globant Unveil New White Paper on Agentic AI in Tourism In 2024, tourism generated 10.9 trillion dollars, nearly 10 percent of global GDP, and is projected to reach 16.5 trillion dollars by 2035. AI
Bureau Veritas:Robust and Consistent Revenue Performance Delivered in Q3 2025; FY 2025 Outlook Reaffirmed23.10.2025 07:30:00 CEST | Press release
Bureau Veritas (BOURSE:BVI): This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251022995674/en/ Hinda Gharbi, CEO Bureau Veritas Q3 2025 Key figures1 › Revenue of EUR 1,583.7 million, up 2.3% year-on-year and up 6.3% organically › A very strong organic growth from Marine & Offshore at 16.2%; solid recovery of Buildings & Infrastructure at 7.1% organically; strong organic growth maintained for both Industry and Certification, at 6.9% and 5.9% respectively, against challenging comparables; moderate organic growth for Consumer Products Services at 3.5% and Agri-Food & Commodities at 2.5% › Positive scope effect of 0.8%, from the accelerated pace of bolt-on acquisitions (+3.1% contribution) realized, net of disposals (-2.3% contribution) › Negative currency impact of 4.8%, resulting from the euro’s appreciation against most currencies Q3 2025 Highlights › Continued progress in implementing the LEAP I 28 strategy, delivering results
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom